Study compares two HER2 breast cancer treatments after surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This Phase 2 study tests two different medicines given after breast surgery to reduce the risk of cancer coming back. It is only for people with early-stage HER2-positive breast cancer with limited or no lymph node spread.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have HER2-positive invasive breast cancer in Stage I, confirmed by special testing.
- Your lymph nodes are either negative (no spread) or have only micrometastases (very tiny spots).
- You must have had your tumor removed with lumpectomy or mastectomy, with clear resection margins.
- You must be able to get ready for study treatment within 90 days after your most recent breast surgery.
- Your health tests must be strong enough for treatment: good blood counts, liver function, and heart function (LVEF at least 50%).
- You can provide tumor tissue samples for research and be willing to sign consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at whether Herceptin (trastuzumab) can be used as after-treatment with less chemotherapy for certain early breast cancers. It may help reduce how much chemotherapy you need, while still lowering the chance the cancer comes back.
This Phase 2 study tests a shorter schedule of trastuzumab and pertuzumab combined with chemotherapy (taxanes) to reduce breast cancer coming back after surgery. It mainly helps people with early-stage, HER2-positive breast cancer that has not spread, by testing whether a shorter plan still works well and is tolerable.
This Phase 2 study compares trastuzumab deruxtecan to standard chemotherapy given before surgery for HER2-positive breast cancer. It aims to see which treatment works better to shrink the tumor and spread before the operation.
This trial tests if a newer drug, Trastuzumab Rezetecan, works as well as an approved drug, Trastuzumab Deruxtecan, when given before surgery for HER2-positive breast cancer. It aims to see which one helps shrink tumors more effectively.
This trial tests whether adding pyrotinib to trastuzumab after surgery can reduce breast cancer coming back in people with HER2-positive, early-stage breast cancer. It may help some patients by improving treatment effectiveness, but it also requires meeting specific heart, lab, and health criteria.
This Phase 2 trial studies a second anti-HER2 treatment (given after surgery) to help lower the risk of breast cancer coming back in people with very small, node-negative, HER2-positive tumors. It will also closely monitor heart function and other side effects because these medicines can affect the body.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.